公开(公告)号：US10774081B2

公开(公告)日：2020-09-15

申请号：US16345271

申请日：2017-10-30

Applicant: LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD. ,  SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.

Inventor： Jianyu Lu ,  Charles Z. Ding ,  Xu Zeng ,  Huijun He ,  Shuhui Chen ,  Lihong Hu ,  Jiaqiang Dong ,  Tie-Lin Wang

IPC: C07D471/04 ,  A61P35/00

Abstract: Disclosed in the present invention is a type of indole substituted piperidine compounds as an estrogen receptor down-regulator. Specifically disclosed are a compound as shown in formula (I), a pharmaceutically acceptable salt, hydrate or prodrug thereof, a preparation method therefor, a pharmaceutical composition thereof, and a use thereof as an estrogen receptor down-regulator in the treatment of estrogen receptor positive breast cancers.

公开(公告)号：US10316033B2

公开(公告)日：2019-06-11

申请号：US15561003

申请日：2016-03-24

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA,CHINESE ACADEMY OF SCIENCES ,  SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.

Inventor： Jingkang Shen ,  Tao Meng ,  Ting Yu ,  Lanping Ma ,  Xin Wang ,  Lin Chen

IPC: C07D471/04 ,  C07D519/00

Abstract: Provided is a process of synthesizing a substituted pyridine and pyrimidine compound. Particularly, provided is a method for preparing a compound of formula III via a compound of formula II′, wherein the definition of each of groups is as described as the description. Compound with other methods, the method in the present invention has features of high yield and a result product being easier to separate.

公开(公告)号：US20190106414A1

公开(公告)日：2019-04-11

申请号：US16087861

申请日：2017-03-24

Applicant: LUOXIN BIOTECHNOLOGY (SHANGHAI) CO., LTD ,  SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD.

Inventor： Jianyu LU ,  Charles Z. DING ,  Lihong HU ,  Huijun HE ,  Shuhui CHEN ,  Jiaqiang DONG ,  Tie-Lin WANG

IPC: C07D409/06 ,  C07D209/18 ,  C07D401/06 ,  C07D403/12 ,  C07D405/06

CPC classification number: C07D409/06 ,  A61K31/404 ,  A61P35/00 ,  C07D209/18 ,  C07D401/06 ,  C07D403/12 ,  C07D405/06

Abstract: Disclosed is a new indole compound, in particular, the compound as shown in formula (I), and a preparation method, pharmaceutical composition and use thereof as an estrogen receptor down-regulator in preparing drugs for treating estrogen receptor-positive breast cancer.